New (or old?) drugs for bad bugs

Rosario Menendez Villanueva (Valencia, Spain)

Source: International Congress 2015 – Antibiotic resistance in respiratory infections
Session: Antibiotic resistance in respiratory infections
Session type: Hot topics
Number: 3444
Disease area: Respiratory infections

WebcastSlide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Rosario Menendez Villanueva (Valencia, Spain). New (or old?) drugs for bad bugs. International Congress 2015 – Antibiotic resistance in respiratory infections

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
New inhaler devices: the good, the bad, and the ugly
Source: International Congress 2015 – Inhaled drugs: within and beyond the lungs
Year: 2015

New drug targets for chronic cough: research you can literally sink your teeth into!
Source: Eur Respir J, 50 (3) 1701571; 10.1183/13993003.01571-2017
Year: 2017



Foundation doctor knowledge of inhaled devices - Are the old better than the new?
Source: International Congress 2016 – Abstracts in medical education, the web and the internet
Year: 2016


New drugs for severe asthma – what should we target and how?
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014


Bronchiectasis: the new, the old and the ugly
Source: International Congress 2018 – State of the art session: Respiratory infections
Year: 2018


Who's (still) afraid of talc?
Source: Eur Respir J 2007; 29: 619-621
Year: 2007


TB: the old enemy
Source: International Congress 2015 – FIRS and Global Lung Health
Year: 2015



One bug, many drugs
Source: Virtual Congress 2021 – CCC Paediatric respiratory diseases
Year: 2021


Who, where, how and why smokes in high school? Who cares about them?
Source: Eur Respir J 2004; 24: Suppl. 48, 609s
Year: 2004

Treating non-adherence: the rest is pointless if the drugs stay in the cupboard!
Source: International Congress 2017 – Cystic fibrosis in children and adults: treatment dilemmas
Year: 2017


What about our challengers?
Source: Virtual Congress 2020 – What’s new with ground-glass opacities?
Year: 2020


Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
Source: Eur Respir Rev 2015; 24: 375-377
Year: 2015


Tobacco control and the ERS: new problems and old foes
Source: Eur Respir J, 57 (1) 2003499; 10.1183/13993003.03499-2020
Year: 2021



New kids on the block in the ECMC and opportunities ?for early career members in 2018
Source: Breathe, 14 (1) 55; 10.1183/20734735.019517
Year: 2018



The air of Europe: where are we going?
Source: Eur Respir Rev, 26 (146) 170024; 10.1183/16000617.0024-2017
Year: 2017



Don’t procrastinate, ventilate! - a quality improvement project.
Source: International Congress 2019 – Treatment of acute respiratory failure with noninvasive ventilation
Year: 2019

“Novel therapies for severe asthma in children and adults.” Vasiliki Delimpoura, Clementine Bostantzoglou, Norrice Liu, Raffaella Nenna. Breathe 2018; 14: 59–62.
Source: Breathe, 14 (2) 165; 10.1183/20734735.518917
Year: 2018


ß2-agonists do not work in children under 2 years of age: myth or maxim?
Source: Breathe, 15 (4) 273; 10.1183/20734735.0255-2019
Year: 2019